Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Sponsor

University of California, San Diego (Other)

Overall Status

Recruiting

CT.gov ID

NCT04501939

Collaborator

Oncternal Therapeutics, Inc (Industry)

Enrollment

Location

Arm

59.5

Anticipated Duration (Months)

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Single center, open-label, phase 2 study to determine the efficacy of cirmtuzumab consolidation in patients with measurable disease on venetoclax.

Condition or Disease	Intervention/Treatment	Phase
Chronic Lymphocytic Leukemia	Drug: Cirmtuzumab Drug: Venetoclax	Phase 2

Detailed Description

This is a phase 2 study to test whether cirmtuzumab in combination with venetoclax given as consolidation therapy can decrease the number of cancer cells that may be left in the bone marrow or in the blood in patients who have been treated with venetoclax for at least one year. Consolidation therapy is given after initial cancer treatment to further reduce the number of cancer cells that may be left in the body. Cirmtuzumab, a monoclonal antibody that inhibits receptor tyrosine kinase like orphan receptor (ROR1) signaling and stemness, may be effective in reducing the risk of disease progression in patients with detectable minimal residual disease (MRD) after treatment with venetoclax.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

16 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Actual Study Start Date :

Aug 6, 2020

Anticipated Primary Completion Date :

Jul 22, 2025

Anticipated Study Completion Date :

Jul 22, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cirmtuzumab + Venetoclax All patients will receive a minimum of 6 cycles (cycle = 28 days) of therapy with venetoclax and cirmtuzumab during the treatment period. For patients who achieve undetectable minimal residual disease (uMRD) positive after cycle 6, an additional 6 cycles of venetoclax and cirmtuzumab may be administered.	Drug: Cirmtuzumab Cycle 1, Day 1 & 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg Drug: Venetoclax Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.

Arm

Intervention/Treatment

Experimental: Cirmtuzumab + Venetoclax

All patients will receive a minimum of 6 cycles (cycle = 28 days) of therapy with venetoclax and cirmtuzumab during the treatment period. For patients who achieve undetectable minimal residual disease (uMRD) positive after cycle 6, an additional 6 cycles of venetoclax and cirmtuzumab may be administered.

Drug: Cirmtuzumab

Cycle 1, Day 1 & 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg

Drug: Venetoclax

Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.

Outcome Measures

Primary Outcome Measures

Percentage of subjects with undetectable measurable residual disease after 6 months of cirmtuzumab + venetoclax treatment. [6-24 months]

Secondary Outcome Measures

Number of subjects with treatment-related adverse events as assessed by CTCAE v5.0. [9-15 months]
Time to next CLL treatment. [9-24 months]

Other Outcome Measures

Change in gene expression in leukemic cells [9-15 months]
The change in gene expression of leukemia cells by single cell PCR or RNA after treatment with cirmtuzumab, including analysis of archival pre-venetoclax sample, when available.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Must have detectable CLL/SLL (> 0.01% leukemia cells present)
Must have received at least 12 months of venetoclax.
Patients may be receiving venetoclax at the time of screening and study entry.
Patients who have discontinued venetoclax more than 6 months prior to study entry must still have a disease burden meeting criteria for low risk of TLS (i.e. no lymph node greater than 5 cm in diameter; absolute lymphocyte count less than 25 k/uL)

Exclusion Criteria:

Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

Uncontrolled and/or active systemic infection (viral, bacterial or fungal)
Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.
Child class B or C cirrhosis

Treatment with any of the following within 7 days prior to the first dose of cirmtuzumab:

Steroid therapy for anti-neoplastic intent
Biologic agent (monoclonal antibody) within 30 days for anti-neoplastic intent.
Chemotherapy (purine analog or alkylating agent) or target small molecule agent within 14 days or 5 half-lives (whichever is shorter), or has not recovered to less than CTCAE grade 2 clinically significant adverse effect(s)/toxicity(s) of previous therapy.
CLL therapy, aside from venetoclax.
History of other malignancy that could affect compliance with the protocol or interpretation of results (example: patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are generally eligible.)
Women who are pregnant or lactating